Open AccessAddressing Neisseria gonorrhoeae Treatment Resistance With the DNA Gyrase A Assay: An Economic Study, United States
Author(s) -
Adriane Wynn,
Jeffrey D. Klausner
Publication year - 2019
Publication title -
sexually transmitted diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.507
H-Index - 105
eISSN - 1537-4521
pISSN - 0148-5717
DOI - 10.1097/olq.0000000000001090
Subject(s) - neisseria gonorrhoeae , dna gyrase , ciprofloxacin , medicine , gonorrhea , microbiology and biotechnology , antibiotics , antibiotic resistance , virology , genetics , biology , escherichia coli , gene , human immunodeficiency virus (hiv)
Targeted antibiotics could delay emergence of resistant Neisseria gonorrhoeae. The DNA gyrase subunit A assay predicts susceptibility to ciprofloxacin. A model found that adding a $50 gyrase subunit A test for asymptomatic patients screened for N. gonorrhoeae resulted in cost neutrality. When ciprofloxacin susceptibility was high, a $114 test resulted in savings.